vha-14 Antibody

What is vha-14 and why are antibodies against it important in research?

vha-14 (UniProt ID: P34462) is a 28,786 Da protein that functions as a subunit of the vacuolar H⁺-ATPase (V-ATPase) complex in Caenorhabditis elegans . V-ATPases are essential for numerous cellular processes including vesicular trafficking, pH homeostasis, and membrane potential regulation.

Antibodies against vha-14 are crucial research tools that allow scientists to:

• Visualize protein localization in cellular compartments

• Measure expression levels in different developmental stages

• Study protein-protein interactions within the V-ATPase complex

• Investigate functional changes in response to environmental stressors

Unlike research on viral antigens where multiple antibody types might be available (monoclonal, polyclonal with various isotypes) , the commercially available vha-14 antibodies are primarily rabbit polyclonal antibodies , which offer broad epitope recognition but may have batch-to-batch variation.

What applications are vha-14 antibodies validated for?

Based on available product information, vha-14 antibodies have been validated for the following applications :

The application scope is more limited compared to well-characterized antibodies like those against viral targets, which are often validated for additional techniques including flow cytometry and neutralization assays .

How should vha-14 antibodies be properly stored and handled?

Proper storage and handling are critical for maintaining antibody functionality. For vha-14 antibodies:

• Short-term storage (1-2 weeks): 4°C is recommended

• Long-term storage: -20°C is optimal

• Formulation: Typically supplied in 50% glycerol, 0.01M PBS, pH 7.4 with 0.03% Proclin 300 as preservative

• Thawing procedure: Thaw at room temperature and briefly centrifuge if liquid becomes entrapped in the cap

• Aliquoting: For frequent users, make small aliquots to avoid repeated freeze-thaw cycles

• Transportation: Usually shipped on dry ice to maintain functionality

The glycerol content in the formulation prevents freeze-thaw damage, but repeated cycles should still be minimized to maintain epitope recognition properties.

What positive and negative controls should be used with vha-14 antibodies?

Proper experimental controls are essential for interpreting antibody-based results:

Positive controls:

• Wild-type C. elegans lysate expressing normal levels of vha-14

• Recombinant vha-14 protein (if available)

• Tissues known to express high levels of V-ATPase components

Negative controls:

• vha-14 knockout or knockdown C. elegans (if viable)

• Lysates from non-target species with low sequence homology

• Primary antibody omission control

• Isotype-matched irrelevant rabbit IgG

As demonstrated in other antibody validation studies , using genetic knockouts or RNA interference-based knockdowns provides the strongest evidence for antibody specificity.

What is the predicted cross-reactivity of vha-14 antibodies?

Cross-reactivity must be considered when using antibodies across different experimental systems:

• Primary reactivity: C. elegans vha-14 (P34462)

• Potential cross-reactivity:

  • Other nematode species with high sequence homology

  • V-ATPase subunits with similar structural motifs

  • Non-specific binding to abundant proteins (requires validation)

Unlike studies with antibodies against highly conserved viral proteins , where cross-reactivity can be advantageous for studying variants, cross-reactivity in vha-14 antibodies may complicate data interpretation and requires careful validation.

How can epitope mapping be performed for vha-14 antibodies?

Epitope mapping is critical for understanding exactly which protein regions an antibody recognizes. For vha-14 antibodies, researchers can employ methods similar to those used in larger antibody characterization studies :

• Fragment-based approach:

  • Express GST-fusion proteins containing different fragments of vha-14

  • Perform Western blot analysis with the antibody against these fragments

  • Narrow down to smaller fragments (15-20 amino acids) to identify the minimal epitope

• Peptide array analysis:

  • Synthesize overlapping peptides (12-15 amino acids) spanning the vha-14 sequence

  • Probe arrays with the antibody to identify reactive peptides

  • Confirm with competitive ELISA using soluble peptides

• Alanine scanning mutagenesis:

  • Create point mutations in identified epitope regions

  • Express mutant proteins and test antibody binding

  • Identify critical residues essential for antibody recognition

As demonstrated in studies characterizing viral antibodies , epitope mapping can reveal if an antibody recognizes linear or conformational epitopes, which influences application suitability.

What are the challenges in using vha-14 antibodies for protein localization studies?

Protein localization studies with vha-14 antibodies face several technical challenges:

• Accessibility issues: Unlike viral envelope proteins that may have exposed epitopes , V-ATPase components exist in multi-subunit complexes where epitopes may be partially masked.

• Fixation sensitivity: Different fixation methods can affect epitope accessibility:

  • Paraformaldehyde: Preserves structure but may mask some epitopes

  • Methanol: Better for some intracellular epitopes but disrupts membranes

  • Acetone: Good for some protein epitopes but can alter membrane structures

• Background reduction strategies:

  • Pre-adsorption with C. elegans embryo powder

  • Optimization of blocking reagents (5% BSA often superior to serum-based blockers)

  • Extended washing steps with 0.05% Tween-20

• Signal amplification options:

  • Tyramide signal amplification for low-abundance targets

  • Secondary antibody selection with minimal cross-reactivity to nematode proteins

  • Use of high-sensitivity detection systems (similar to approaches in )

How can vha-14 antibodies be validated for specificity in C. elegans research?

• Genetic validation:

  • Test antibody on vha-14 knockout/knockdown worms (if viable)

  • Use CRISPR/Cas9 to tag endogenous vha-14 with GFP and confirm co-localization

  • Overexpress vha-14 and confirm increased signal

• Biochemical validation:

  • Mass spectrometry confirmation of immunoprecipitated proteins

  • Competitive binding with recombinant vha-14 protein

  • Pre-absorption controls with purified antigen

• Orthogonal method comparison:

  • Compare antibody results with RNA expression data

  • Validate with GFP-tagged transgenic lines

  • Compare results from multiple vha-14 antibodies targeting different epitopes

This multi-faceted approach is similar to validation standards applied in antibody development for viral proteins and ensures confidence in experimental results.

How can researchers optimize Western blot protocols for vha-14 detection?

Western blot optimization for vha-14 detection requires attention to several parameters:

• Sample preparation considerations:

  • Buffer composition: Include protease inhibitors to prevent degradation

  • Denaturing conditions: 95°C for 5 minutes in SDS buffer typically effective

  • Loading amount: Start with 20-50 μg total protein per lane

• Gel percentage optimization:

  • 12-15% polyacrylamide gels provide optimal resolution for the 28.8 kDa vha-14 protein

  • Consider gradient gels (4-20%) when analyzing vha-14 in complex with other V-ATPase subunits

• Transfer conditions:

  • Semi-dry transfer: 15V for 30 minutes often sufficient

  • Wet transfer: 100V for 1 hour in cold room recommended for quantitative analysis

  • Membrane selection: PVDF typically provides better results than nitrocellulose for this target

• Detection optimization:

  • Primary antibody concentration: Titrate from 1:500 to 1:2000

  • Incubation conditions: Overnight at 4°C often yields cleaner results than shorter incubations

  • Secondary antibody selection: Use highly cross-adsorbed antibodies to minimize background

Similar optimization approaches have been employed successfully for other challenging antibody targets in nematode research.

What strategies can be employed when vha-14 antibodies produce unexpected results?

When researchers encounter unexpected results with vha-14 antibodies, systematic troubleshooting is necessary:

• Unexpected band patterns:

  • Compare with predicted molecular weight (28.8 kDa)

  • Consider post-translational modifications (phosphorylation, glycosylation)

  • Test alternative sample preparation methods to address protein degradation

  • Check for splice variants in your experimental conditions

• Weak or no signal:

  • Increase antibody concentration or extend incubation time

  • Try alternative antigen retrieval methods for fixed samples

  • Consider more sensitive detection systems (chemiluminescent vs. colorimetric)

  • Test antibody on positive control samples to check functionality

• High background:

  • Increase blocking time/concentration (5% BSA or milk protein)

  • Add 0.05-0.1% Tween-20 to washing buffers

  • Increase washing steps (5-6 washes of 5-10 minutes each)

  • Dilute primary antibody further or try alternative blocking reagents

• Inconsistent results between experiments:

  • Standardize lysate preparation and protein quantification methods

  • Create standard operating procedures for all steps

  • Consider using automated Western blot systems for better reproducibility

  • Use the same lot of antibody when possible, or validate new lots against old ones

These troubleshooting approaches have been successfully applied in antibody-based systems similar to those referenced in the search results .

How can vha-14 antibodies be used to study protein-protein interactions within the V-ATPase complex?

Studying protein-protein interactions with vha-14 antibodies requires specialized approaches:

• Co-immunoprecipitation (Co-IP) optimization:

  • Lysis conditions: Use gentle, non-ionic detergents (0.5-1% NP-40 or Triton X-100)

  • Buffer composition: Include stabilizing agents to maintain complex integrity

  • Pre-clearing: Reduce non-specific binding with protein A/G beads before adding antibody

  • Cross-linking: Consider reversible cross-linking to stabilize transient interactions

• Proximity ligation assay (PLA):

  • Combine vha-14 antibody with antibodies against other V-ATPase subunits

  • PLA signal occurs only when proteins are within 40 nm of each other

  • Provides spatial information about interaction in situ

  • Quantify interaction events per cell using fluorescence microscopy

• Antibody-based pull-down followed by mass spectrometry:

  • Immunoprecipitate vha-14 under native conditions

  • Analyze precipitated complexes by LC-MS/MS

  • Compare interactome under different physiological conditions

  • Validate key interactions with reciprocal Co-IP

These techniques have been successfully employed in characterizing protein-protein interactions in other complex systems, as referenced in antibody-based research methods .

What are the latest methodological advances relevant to vha-14 antibody applications?

Recent methodological advances that can be applied to vha-14 antibody research include:

• Super-resolution microscopy techniques:

  • STORM and PALM microscopy can resolve vha-14 localization below the diffraction limit

  • Requires highly specific antibodies with minimal background

  • Can reveal subcellular distribution patterns invisible to conventional microscopy

  • Optimization of labeling density is critical for successful implementation

• Microfluidic antibody analysis systems:

  • Real-time binding kinetics can be measured using small sample volumes

  • Allows high-throughput screening of antibody functionality

  • Can be used to compare different lots or clones of vha-14 antibodies

  • Provides quantitative binding parameters (kon, koff, KD)

• Computational antibody epitope prediction:

  • In silico methods to predict antibody binding sites on vha-14

  • Can guide experimental design for creating more specific antibodies

  • Helps identify potentially cross-reactive regions

  • Computational framework approaches similar to those described in

• Antibody engineering for improved specificity:

  • Techniques for improving antibody affinity and specificity

  • Methods similar to those used in creating bispecific antibodies

  • Potential for developing recombinant antibodies with enhanced properties

  • Computational design frameworks to optimize antibody performance

These advanced techniques represent the cutting edge of antibody-based research methodologies and can significantly enhance the utility of vha-14 antibodies in C. elegans research.

How can transfection of vha-14 antibodies be used to study disease pathogenesis?

Direct antibody transfection into cells represents an advanced technique that can be applied to vha-14 research:

• Methodology for antibody transfection:

  • Protein transfection reagents (Chariot, ProJect) can deliver antibodies directly into cells

  • Electroporation can be effective for certain cell types

  • Microinjection provides precise delivery into individual cells or C. elegans gonads

  • Cell-penetrating peptide conjugation can enhance antibody uptake

• Applications in disease models:

  • Blocking specific vha-14 functions in live cells

  • Studying acute effects of vha-14 inhibition without genetic manipulation

  • Comparing effects with pharmacological V-ATPase inhibitors

  • Targeting specific vha-14 interaction domains

• Experimental design considerations:

  • Include fluorescently-labeled control antibodies to confirm transfection

  • Optimize antibody concentration to avoid non-specific effects

  • Perform time-course experiments to determine optimal analysis timepoints

  • Include appropriate controls (isotype, non-targeting antibodies)

This approach has been successfully used to study the pathogenesis of autoimmune diseases and could be adapted for vha-14 research as described in reference .

How should researchers approach validation when contradictory results emerge with vha-14 antibodies?

When contradictory results arise with vha-14 antibodies, a structured validation approach is necessary:

• Technical validation:

  • Cross-validate with multiple detection methods (WB, IF, IP)

  • Test multiple antibody lots and sources if available

  • Perform antibody validation in vha-14 overexpression and knockdown systems

  • Evaluate technical factors (sample preparation, fixation methods, detection systems)

• Biological validation:

  • Consider developmental timing and tissue-specific expression patterns

  • Evaluate potential post-translational modifications affecting epitope recognition

  • Test under different physiological conditions (stress, developmental stages)

  • Compare with RNA expression data from transcriptomic studies

• Collaborative validation:

  • Exchange samples and protocols with collaborating laboratories

  • Perform blinded analysis of shared samples

  • Use standardized positive and negative controls across laboratories

  • Conduct interlaboratory comparison studies

• Reporting standards:

  • Document all validation steps thoroughly

  • Report negative and contradictory results

  • Include comprehensive methods sections detailing antibody validation

  • Follow established antibody reporting guidelines

This comprehensive approach to validation is similar to the rigorous standards applied in antibody characterization studies for viral antigens and helps resolve contradictory findings.

How can researchers quantitatively assess vha-14 antibody binding characteristics?

Quantitative assessment of antibody binding parameters provides important information about research utility:

• Surface Plasmon Resonance (SPR) analysis:

  • Measures real-time binding kinetics (kon, koff) and affinity (KD)

  • Requires purified recombinant vha-14 protein

  • Can compare multiple antibody lots or sources

  • Provides quantitative metrics for antibody performance comparison

  • Similar approaches have been used for assessing antibody performance in other systems

• Bio-Layer Interferometry (BLI):

  • Alternative to SPR that doesn't require microfluidic systems

  • Can measure binding kinetics with small sample volumes

  • Useful for comparing antibody performance across experimental conditions

  • Allows real-time monitoring of association and dissociation

• Quantitative ELISA approaches:

  • Standard curves with purified recombinant vha-14

  • Four-parameter logistic regression analysis for accurate quantification

  • Determination of EC50 values for different antibody lots

  • Assessment of linear detection range for experimental planning

• Comparative binding analysis:

  • Competitive binding assays to determine relative epitope binding

  • Assessment of pH and buffer condition effects on binding

  • Temperature sensitivity analysis for experimental planning

  • Comparative performance metrics across different detection systems

These quantitative approaches provide objective metrics for antibody performance and help researchers select optimal reagents and conditions for their specific experimental needs.